Dr. O'Shaughnessy on Continued Access to Avastin

Joyce A. OShaughnessy, MD
Published: Saturday, Aug 13, 2011

Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that all she truly needs is access to Avastin (bevacizumab) as a treatment option for breast cancer. She believes that with its many other approvals, both in the US and in the Europe, it will continue to be accessible with a large amount of information available on its use. Having tools, such as Avastin, readily available that are non-cross resistant with chemotherapy is necessary for patients with very few options left.
SELECTED
LANGUAGE
Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that all she truly needs is access to Avastin (bevacizumab) as a treatment option for breast cancer. She believes that with its many other approvals, both in the US and in the Europe, it will continue to be accessible with a large amount of information available on its use. Having tools, such as Avastin, readily available that are non-cross resistant with chemotherapy is necessary for patients with very few options left.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x